DNLI
Denali Therapeutics Inc.
Key Financials
Operating Income
$-555342000
↓ 14.0%
Net Income
$-512540000
↓ 21.2%
EPS (Diluted)
$-2.97
↓ 15.6%
Total Assets
$1.1B
↓ 16.7%
Revenue
$0
NaN%
Total Liabilities
$131.1M
↓ 9.3%
Cash & Equivalents
$205.3M
↑ 17.4%
Shareholders' Equity
$1.0B
↓ 17.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
| undefined | Invalid Date | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | DNLI |
| Company Name | Denali Therapeutics Inc. |
| CIK | 1714899 |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (650) 866-8547 |